1,2-Dithiolane Compounds Inhibit Mutant EGFR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mutant EGFR-mediated diseases, such as non-small cell lung cancer, are limited by drug resistance and adverse side effects, particularly for exon 19 and exon 21 mutations, which are prevalent in East Asian populations and account for over 90% of EGFR mutations.
Innovation Solution
Development of 1,2-dithiolane and related dithiol compounds and their pharmaceutical compositions that effectively inhibit mutant EGFR activity, preventing tumor cell proliferation, angiogenesis, and metastasis, while offering a potential alternative to existing therapies with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mutant EGFR-mediated diseases are used, then tumor cell proliferation can be inhibited, but drug resistance develops and adverse side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of EGFR inhibitors to create novel 1,2-dithiolane and dithiol compounds with optimized molecular properties. These structural parameter changes result in compounds that maintain efficacy against mutant EGFR while overcoming resistance mechanisms that developed against previous generation inhibitors
Solution Approach 2:
The patent employs composite materials by designing hybrid molecular structures that combine specific functional groups (1,2-dithiolane and dithiol moieties) with various substituent patterns. This composite approach creates inhibitors with enhanced selectivity and activity profiles that address both efficacy and resistance issues simultaneously
2Reliability
If current treatments for mutant EGFR-mediated diseases are used, then tumor cell proliferation can be inhibited, but adverse side effects occur
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (1,2-dithiolane and dithiol) at targeted positions within the molecular structure. These localized structural modifications enhance binding affinity to mutant EGFR while reducing off-target effects, thereby improving the therapeutic index and reducing adverse side effects
Solution Approach 2:
The patent modifies molecular parameters such as lipophilicity, molecular weight, and hydrogen bonding capacity through systematic variation of substituent groups. These parameter optimizations improve pharmacokinetic properties and reduce toxicity while maintaining antitumor efficacy
3Productivity
If existing EGFR inhibitor therapies are used, then cancer progression can be controlled, but treatment options are limited for resistant cases
Solution Approach 1:
The patent achieves universality by designing a platform of compounds (1,2-dithiolane and dithiol derivatives) that can target multiple EGFR mutation types (exon 19 deletions, exon 21 L858R, and T790M). This multi-functional approach expands treatment coverage across different resistance scenarios while maintaining a unified mechanistic framework
Data Source
AI summary
Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.